Ace­lyrin says CRO Fortrea made er­rors in tri­al of lead im­munol­o­gy drug izok­ibep

Ace­lyrin said a con­tract re­search or­ga­ni­za­tion con­duct­ing stud­ies of its lead ex­per­i­men­tal drug had made “clin­i­cal tri­al ex­e­cu­tion er­rors” and it was con­duct­ing an au­dit of the work, a set­back that’s like­ly to cost the biotech time and mon­ey.

Mon­day af­ter­noon’s an­nounce­ment is bit­ter news for the com­pa­ny, which went pub­lic in May and raised $540 mil­lion, on­ly to see its stock crater af­ter the drug, an IL-17A in­hibitor named izok­ibep, failed in a tri­al of pa­tients with hidradeni­tis sup­pu­ra­ti­va ear­li­er this fall.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER